Pimavanserin Tartrate
Grundinformationen
- CAS
706782-28-7- Standard-SMILES
CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1.CC(C)COc1ccc(CNC(=O)N(Cc2ccc(F)cc2)C2CCN(C)CC2)cc1.O=C(O)[C@H](O)[C@@H](O)C(=O)O- InChIKey
RGSULKHNAKTFIZ-CEAXSRTFSA-N- Summenformel
- C54H74F2N6O10
- Durchschnittliche Molmasse
- 1.005,2 g/mol
- Monoisotopische Masse
- 1.004,5434489
Überblick
Pimavanserin tartrate is a tartrate salt that is the hemitartrate salt of pimavanserin. An atypical antipsychotic that is used for treatment of hallucinations and delusions associated with Parkinson's disease. It has a role as a 5-hydroxytryptamine 2A receptor inverse agonist, an antipsychotic agent and a serotonergic antagonist. It contains a pimavanserin(1+).
Namen und Bezeichner
- Bevorzugter Name
- Pimavanserin Tartrate
- IUPAC
- (2R,3R)-2,3-dihydroxybutanedioic acid;bis(1-[(4-fluorophenyl)methyl]-1-(1-methylpiperidin-4-yl)-3-[[4-(2-methylpropoxy)phenyl]methyl]urea)
- Englischer Name
- Unii-na83F1sjsr
- Summenformel
- C29H40FN3O8
- Molmasse
- 577.65
Namen und Synonyme
Pimavanserin tartrate706782-28-7NuplazidNA83F1SJSRCHEBI:133014DTXSID50220958Bis(1-(4-Fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-(4-(2-methylpropoxy)benzyl)urea) (2R,3R)-2,3-dihydroxybutanedioateUrea, N-((4-fluorophenyl)methyl)-N-(1-methyl-4-piperidinyl)-N'-((4-(2-methylpropoxy)phenyl)methyl)-, (2R,3R)-2,3-dihydroxybutanedioate (2:1)Bis[1-(4-fluorobenzyl)-1-(1-methylpiperidin-4-yl)-3-[4-(2-methylpropoxy)benzyl]urea] (2R,3R)-2,3-dihydroxybutanedioateRefChem:59075DTXCID80143449UNII-NA83F1SJSR
Weitere Namen anzeigen
ACP-103BVF-048ACP-103 tartrate8-Octanedioic acidPimavanserin tartrarePimofonserin L-tartratePimavanserin tartrate vv
pimavanserin hemitartrate706782-28-7 (tartrate)Nuplazide (TN)Pimavanserin tartrate [USAN]ACP-103 hemitartratePimavanserin tartaric acidPimavanserin Dihydroxysuccinate(2:1)Pimavanserin tartrate (USAN)
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 205 Ų
- H-Brücken-Donoren
- 6
- H-Brücken-Akzeptoren
- 14
- Frei drehbare Bindungen
- 19
- Schwere Atome
- 72
- Formalladung
- 0
- Komplexität
- 657
Experimentelle und physikochemische Eigenschaften
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antiparkinson Agents; Antipsychotic Agents; Serotonin 5-HT2 Receptor Antagonists
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physikochemische Eigenschaften
- storage temp.
- -20 °C · Store at -20°C
- Löslichkeit
- 70 · DMSO:70.0(Max Conc. mg/mL);69.6(Max Conc. mM)
- Aggregatzustand
- Solid
- Farbe
- White to off-white
- InChIKey
- XTTVNKCYECPJOF-MVELKYERNA-N
- SMILES
- [C@H](O)(C(=O)O)[C@@H](O)C(=O)O.N(C1CCN(C)CC1)(C(=O)NCC1C=CC(OCC(C)C)=CC=1)CC1C=CC(F)=CC=1 |&1:0,5,r|
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
This chemical does not meet GHS hazard criteria for 50% (1 of 2) of reports.
Danger
H302+H332 (50%): Harmful if swallowed or if inhaled [Warning Acute toxicity, oral; acute toxicity, inhalation]
P261, P264, P264+P265, P270, P271, P272, P280, P301+P317, P302+P352, P304+P340, P305+P354+P338, P317, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Hazard Classes and CategoriesAcute Tox. 4 (50%)
Toxikologische Informationen
Drug Induced Liver Injury
Drug Induced Liver Injury Rank (DILIrank 2.0)
Pimavanserin tartrate
vNo-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Sicherheitsdaten
- hs_code
- 29299090
Chemie und Industrie
Pharmakologische Informationen
FDA Pharmacological Classification
PIMAVANSERIN TARTRATE
Atypical Antipsychotic [EPC]
MeSH Pharmacological Classification
Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists.
Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus.
Drugs that bind to but do not activate SEROTONIN 5-HT2 RECEPTORS, thereby blocking the actions of SEROTONIN or SEROTONIN 5-HT2 RECEPTOR AGONISTS. Included under this heading are antagonists for one or more specific 5-HT2 receptor subtypes.
Anwendungen
BeschreibungPimavanserin, developed by San Diego-based Acadia Pharmaceuticals, is a selective and potent serotonin 2A (5-HT2A) receptor inverse agonist. The USFDA approved this once-daily drug to treat the delusions and hallucinations associated with psychosis as a function of Parkinson’s disease. Pimavanserin has a unique mechanism of action relative to other antipsychotics, behaving as a selective inverse agonist of the serotonin 5-HT2A receptor while exhibiting 40-fold selectivity over the 5-HT2C receptor and having no significant affinity or activity with the 5-HT2B or dopamine receptors.
VerwendenPimavanserin tartrate is a 5-HT2A inverse agonist that reverses psychosis-like behaviours and has the potential to treat various other neuropsychiatric disorders such as schizophrenia and Parkinson’s disease.
Ergänzende Hinweise
Zugehörige Reaktionen
0
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Notizen zur Verbindung
Wird geladen…